Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation

@article{Piccini2010OralFX,
  title={Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation},
  author={Jonathan P. Piccini and Renato Delascio Lopes and Kenneth W. Mahaffey},
  journal={Current Opinion in Cardiology},
  year={2010},
  volume={25},
  pages={312–320}
}
Purpose of review Prevention of stroke and systemic emboli is paramount in the management of atrial fibrillation. Although warfarin is the predominant anticoagulant used in patients with atrial fibrillation, it has significant limitations that have impeded appropriate use of stroke prophylaxis in eligible patients with atrial fibrillation. Consequently, much research has been focused on finding an alternative to warfarin. We review the potential alternatives in development and evaluate the… 
The evolving field of stroke prevention in patients with atrial fibrillation.
TLDR
Dabigatran is the first agent to show superiority over warfarin for stroke prevention in atrial fibrillation, raising the standard for newer agents.
Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012
TLDR
The anticoagulant agents that are clinically available or under development as alternatives to VKAs for stroke prevention in patients with nonvalvular atrial fibrillation are reviewed.
Edoxaban: a new oral direct factor xa inhibitor.
TLDR
In phase III clinical trials, edoxaban was associated with statistically significant dose-dependent reductions in VTE after orthopaedic surgery compared with placebo or dalteparin sodium and was not associated with hepatotoxicity.
Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.
Newer clinically available antithrombotics and their antidotes
  • S. Lévy
  • Medicine
    Journal of Interventional Cardiac Electrophysiology
  • 2014
TLDR
The management of patients suffering from a major bleeding or requiring a non-elective major surgery includes non-specific reversal agents and is discussed in the light of a recent position paper and of current literature.
Bleeding of New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
TLDR
Oral direct factor Xa inhibitors and oral direct thrombin inhibitors are more effective in reducing stroke and systemic embolism without increasing the risk of major bleeding compared to traditional oral anticoagulants.
Efficacy and safety of novel anticoagulants compared with established agents
TLDR
Dabigatran, rivaroxaban, and apixaban are novel oral anticoagulants that offer major advantages over existing agents and may impact physician prescribing practices and warrant consideration in patients requiring thrombosis management.
Apixaban for Stroke Prevention in Atrial Fibrillation: A Review of the Clinical Trial Evidence
TLDR
Apixaban is the first new oral anticoagulant that has been shown to be superior to warfarin in reducing stroke or systemic embolism, all-cause mortality, and major bleeding in patients with AF.
Gastrointestinal disorders and dabigatran
TLDR
It is suggested that dabigatran etexilate is associated with higher rates of dyspeptic symptoms compared to warfarin and potential counter measures from a gastroenterologist's perspective are reviewed.
...
1
2
3
4
...

References

SHOWING 1-10 OF 85 REFERENCES
Rivaroxaban, an oral direct factor Xa inhibitor.
TLDR
The safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated and the drug may have its greatest impact in providing a much-needed and attractive alternative to warfarin.
Rivaroxaban, an oral direct factor Xa inhibitor
TLDR
The safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated and the drug may have its greatest impact in providing a much-needed and attractive alternative to warfarin.
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TLDR
An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
TLDR
The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in patients with atrial fibrillation requiring chronic anticoagulant therapy, but the potential for hepatotoxicity requires further investigation.
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
TLDR
Compared with aspirin, oral anticoagulant significantly decreases the risk of all strokes, ischemic strokes, and cardiovascular events for patients with nonvalvular chronic or paroxysmal AF but modestly increases the absolute risk of major bleeding.
Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.
TLDR
About half of the patients with atrial fibrillation admitted to these academic hospitals had clinical risk factors that are associated with increased risk of stroke and no contraindications to anticoagulation, and antithrombotic therapy was underused.
Can we rely on RE-LY?
  • B. Gage
  • Medicine
    The New England journal of medicine
  • 2009
In patients with atrial fibrillation, warfarin prevents 64% of strokes.1 Thus, warfarin has become the recommended treatment for candidates for anticoagulation therapy who have atrial fibrillation
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement 1
TLDR
Apixaban in doses of 2.5 mg b.i.d. or 5’h after surgery with apixaban or enoxaparin has a promising benefit–risk profile compared with the current standards of care following TKR, and a significant dose‐related increase in the incidence of total adjudicated bleeding events was noted.
...
1
2
3
4
5
...